Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Coherus Oncology, Inc.
| Metric | Coherus Oncology, Inc. CHRSHealthcare |
|---|---|
| Quality Score | 39 / 100 |
| Revenue (latest) | $42M |
| Net income (latest) | $168M |
| Operating margin | −429.5% |
| Net margin | 398.4% |
| Return on equity | 275.4% |
| Return on assets | 65.0% |
| Return on capital (ROCE) | −153.6% |
| Debt / equity | 3.23× |
| Revenue growth (YoY) | −84.2% |
| Altman Z″ (distress) | -20.15 |
| Accruals / assets | 118.7% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.